Vol 94, No 7 (2023)
Review paper
Published online: 2022-09-21

open access

Page views 1258
Article views/downloads 457
Get Citation

Connect on Social Media

Connect on Social Media

Severe course of COVID-19 in pregnant woman and newborn’s alloimmune thrombocytopenia — case study and review of the literature

Angelika Piotrowska-Gwizdak1, Karolina Krajewska1, Hanna Blaszczyk1, Anna Gluszko2, Konstanty Szuldrzynski3, Waldemar Wierzba4, Artur J. Jakimiuk15
Pubmed: 36134762
Ginekol Pol 2023;94(7):565-569.


So far, little is known about the impact of the coronavirus disease 2019 (COVID-19) on pregnancy and data is often inconsistent. Even less information has been published on the management of severe courses of COVID-19 in pregnant women. By writing this article, we aim to share our experience in the treatment of pregnant woman critically ill with COVID-19 and newborn’s condition, fetal and neonatal alloimmune thrombocytopenia (FNAIT), as well as literature review of this disease. After admission, the woman’s respiratory status rapidly worsened, requiring administration of oxygen and in the end ECMO therapy. At the 9th day of ECMO support, and 28 weeks 3 days of gestation, due to mother’s prognosis and increased feto-placental vascular resistance a decision of Caesarean section was taken. The neonate required intensive care not only due to extreme prematurity but coagulation disorder, alloimmune thrombocytopenia, which we diagnosed a few weeks after delivery.

Article available in PDF format

View PDF Download PDF file


  1. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr. 2020; 8: 104.
  2. Allotey J, Stallings E, Bonet M, et al. for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; 370: m3320.
  3. Szczygiol P, Baranska K, Korczak I, et al. COVID-19 in pregnancy, management and outcomes among pregnant women and neonates — results from tertiary care center in Wroclaw. Ginekol Pol. 2022; 93(1): 47–53.
  4. Nayak MK, Panda SK, Panda SS, et al. Neonatal outcomes of pregnant women with COVID-19 in a developing country setup. Pediatr Neonatol. 2021; 62(5): 499–505.
  5. Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO J. 2020; 66(5): 472–474.
  6. Barrantes JH, Ortoleva J, O'Neil ER, et al. Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. ASAIO J. 2021; 67(2): 132–136.
  7. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020; 396(10257): 1071–1078.
  8. Brojer E, Husebekk A, Dębska M, et al. Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention. Arch Immunol Ther Exp (Warsz). 2016; 64(4): 279–290.
  9. Peterson JA, McFarland JG, Curtis BR, et al. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013; 161(1): 3–14.
  10. Winkelhorst D, de Vos TW, Kamphuis MM, et al. HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk. BMJ Open. 2020; 10(7): e034071.
  11. Kamphuis MM, Paridaans NP, Porcelijn L, et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014; 133(4): 715–721.
  12. Bertrand G, Drame M, Martageix C, et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood. 2011; 117(11): 3209–3213.
  13. Uhrynowska ME, Dębska M, Guz K, et al. [PREVFNAIT prevention of foetal/neonatal alloimmune thrombocytopenia (FNAIT) in Polish foetuses and newborns--the PREVFNAIT program]. Ginekol Pol. 2015; 86(1): 62–66.
  14. Lieberman L, Greinacher A, Murphy MF, et al. International Collaboration for Transfusion Medicine Guidelines (ICTMG). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019; 185(3): 549–562.
  15. Winkelhorst D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017; 129(11): 1538–1547.
  16. Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2021; 225(2): 120–127.
  17. de Vos TW, Winkelhorst D, de Haas M, et al. Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci. 2020; 59(1): 102704.